Novo Nordisk, which makes Ozempic and Wegovy, has filed a federal lawsuit against Eli Lilly, accusing its competitor of false advertising and unfair competition. Novo Nordisk challenges national ad campaigns from Eli Lilly that compare GLP-1 drugs from both companies, saying that Lilly intentionally relies on outdated clinical trials to paint a false and misleading picture. NBC’s Christine Romans joins TODAY with the details.

Tuesday, July 21 – Adolescents and young adults in the U.S. are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center researchers published in JAMA Pediatrics.

Tuesday, July 21 – (MedPage Today) — The market for compounded GLP-1 drugs remained robust despite the end of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, with many facilities adding ingredients like B vitamins and some operating…

Tuesday, July 21 – Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why and where that leaves patients.

Tuesday, July 21 – New research being presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (15–17 July), shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss in children of various ages without diabetes are safe and effective. The study is by Dr. Manpreet Kaur Oberoi of the University of Western Ontario in London, Ontario, Canada, and colleagues.

Tuesday, July 21 – From headlines and social media, psychedelic therapies, cannabis use and GLP-1 medications have seemingly become commonplace overnight, but the science underlying these treatments and the pathway to drug approval are often more nuanced than the headlines suggest.

Monday, July 20 – “I’m the one that has to live in my body, I’m doing what I need to get my life back, and that’s all that matters.”View Entire Post ›

Sunday, July 19 – (MedPage Today) — I spent 10 minutes in complete silence in my patient’s room today, my eyes scanning lines of text in the electronic medical record. I wasn’t looking for a life-threatening lab value or an undiscovered malignancy. I was hunting…

Saturday, July 18 – GLP-1 medications like Ozempic and Wegovy may help ease symptoms of binge eating disorder and related eating behaviors. Giselleflissak/Getty Images

A new study found that GLP-1RAs could reduce key symptoms of binge eating disorder.

These included binge eating severity, loss of control eating, and emotional eating.

Experts say that GLP-1RAs could potentially augment existing treatments for binge eating disorder, like psychotherapy.

Saturday, July 18 – A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, dehydration, and other frailty-associated conditions. Getty Images

A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, and dehydration.

However, the benefits of taking these drugs should be weighed against these risks when the medications are prescribed.

Saturday, July 18 – An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of medication that mimics the GLP-1 hormone—to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

Saturday, July 18 – Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.

Saturday, July 18 – Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

Friday, July 17 – Some people using GLP-1 drugs for weight loss have reported changes in their feet. Image Credit: stockvisual/Getty

“Ozempic feet” is the latest anecdotal side effect of GLP-1 drugs for weight loss.

The unusual phenomenon is a result of rapid weight loss, which may cause foot pain, changes in shoe size, and a more bony appearance in the feet.

Friday, July 17 – Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a potential answer by identifying a distinct biological subtype of obesity that responds especially well to tirzepatide, a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation, moving the field closer to precision medicine for obesity.

Friday, July 17 – As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022. These total payments included out-of-pocket costs paid by patients as well as payments from insurers, employers and government programs.

Friday, July 17 – A meta-analysis of 10 randomized controlled trials involving more than 23,000 participants, presented at the International Congress on Obesity (ICO 2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (July 15–17), shows that the GLP-1 class of obesity drugs is associated with a marked reduction in systemic inflammation beyond its anti-obesity effects, potentially explaining how the drugs can reduce cardiovascular risk factors.

Thursday, July 16 – Public interest in obesity medication has risen 25-fold since the launch of GLP-1 receptor agonist drugs, new research presented at the International Congress on Obesity (ICO2026) in Mexico City, Mexico, hosted by the World Obesity Federation (July 15–17) shows.

Thursday, July 16 – (MedPage Today) — Note that some links may require registration or subscription.
A preprint study flagged signals of frailty in seniors taking the GLP-1 drug tirzepatide (Zepbound) for weight loss. (Reuters via Yahoo!)
The House passed a bill…

Thursday, July 16 – (MedPage Today) — GLP-1 drugs did not appear to improve diabetes patients’ job or marriage prospects, according to a working paper from the National Bureau of Economic Research. (Axios)
The U.S. by 2035 will have 57 million overweight individuals…

Thursday, July 16 – Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China.

Wednesday, July 15 – As a Gen Xer who lived through the “heroin chic” years, when skeletal models were celebrated for jutting bones and sallow skin, the recent popularity of the #Y2KSkinny trend fills me with dread.

Wednesday, July 15 – (MedPage Today) — Note that some links may require registration or subscription.
A cohort study found that diabetes patients taking GLP-1 receptor agonists had a higher risk of anterior ischemic optic neuropathy, a potentially blinding eye condition…

Wednesday, July 15 – Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging. Although the findings are encouraging, scientists say larger studies are needed before concluding that the medication can help people age more slowly.

(Wednesday, July 15 – MedPage Today) — Adding a GLP-1 receptor agonist was not associated with a lower likelihood of discontinuing existing basal insulin therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation trial…

Wednesday, July 15 – In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere—from NPR and The Washington Post to Substack and heated exchanges on social media—all circling the same claim: Ozempic might lower the risk of cancer.

Wednesday, July 15 – Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China.

Monday, July 13 – How GLP-1 drugs like Ozempic could help prevent lung scarring after COVID

Monday, July 13 – Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes. The study included adults with Type 2 diabetes who were not taking diabetes medicines and whose blood sugar was not adequately controlled with diet and exercise alone.

Sunday, July 12 – Whether it’s been about weight, blood sugar, PCOS, food noise, or something else entirely, we want to hear.View Entire Post ›

Sunday, July 12 – (MedPage Today) — Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear.
Across 262 randomized studies published through November…

Friday, July 10 – (MedPage Today) — Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the more recent types of antidiabetic medications.
Rates of new-onset autoimmune conditions were compared…

Friday, July 10 – The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%.

Friday, July 10 – Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use of obesity drugs for weight loss treatment. The statement, which is published in The Lancet Diabetes & Endocrinology, is led by Dr. Laurence Dobbie of the Department of Population Health Sciences, King’s College London, with an international team of 26 authors.

Friday, July 10 – Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible received the treatment, according to new research published in the American Journal of Managed Care by the USC Schaeffer Center for Health Policy & Economics.

Friday, July 10 – (MedPage Today) — Diabetes patients with hepatocellular carcinoma (HCC) experienced longer time to HCC recurrence and longer survival when they initiated a GLP-1 agonist rather than a DPP-4 inhibitor, a target trial emulation study found. (Gut…

Thursday, July 9 – Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes rather than intentional misuse. Simple education about proper weekly dosing and gradual dose increases could help prevent many of these avoidable incidents.

Thursday, July 9 – (MedPage Today) — Americans’ use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll.
For patients with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists…

Thursday, July 9 – The new Medicare GLP-1 Bridge program offers broader, more affordable access to weight loss drugs to address the growing obesity crisis. But there’s a catch when it comes to bone health.